TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1780416

Group type: EXPERIMENTAL
Intervention: Silver acetate chewing gum
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum
Number of subjects: 496

Group type: COMPARATOR
Intervention: Ordinary chewing gum
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Overall treatments (Nicotine, Silver Acetate, Ordinary chewing gum)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 496
Study: 7204955

Group type: COMPARATOR
Intervention: Task instructions indicating Easy or Hard (Subjective) and actual task difficulty (Easy or Hard) (Objective)
Number of subjects: 0
Study: 30138239

Group type: EXPERIMENTAL
Intervention: 3-minute intermaximal repetition rest period (IMRRP-3)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 2-minute intermaximal repetition rest period (IMRRP-2)
Number of subjects: 9
Study: 28791802

Group type: EXPERIMENTAL
Intervention: Modified-release prednisone (Lodotra™)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Immediate-release prednisolone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study: 26966106

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 62

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 62
Study: 24080993

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1000 mg plus prednisone 5 mg b.i.d.
Number of subjects: 797

Group type: COMPARATOR
Intervention: Placebo plus prednisone 5 mg b.i.d.
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) plus prednisone
Number of subjects: 797
Study: 23419915

Group type: EXPERIMENTAL
Intervention: Therapists' estimations of therapy time
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Therapists' estimations of inactive time
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mean difference between therapist-estimated and video-recorded total therapy time
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mean difference between therapist-estimated and video-recorded active time
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mean difference between therapist-estimated and video-recorded inactive time
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of estimation accuracy between individual therapy sessions and circuit class therapy
Number of subjects: 12
Study: 20713475

Group type: EXPERIMENTAL
Intervention: Once-daily budesonide/formoterol (80/4.5 microg x2 inhalations; 160/9 microg daily)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Twice-daily budesonide/formoterol (40/4.5 microg x2 inhalations; 160/18 microg daily)
Number of subjects: 521
Study: 18160245

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (no DA)
Number of subjects: 194
Study: 15690290

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clinical sedation scales (OAA/S, Modified Ramsey, VAS)
Number of subjects: 16
Study: 12757961

Group type: EXPERIMENTAL
Intervention: Marijuana cigarette (0.003, 2, or 3.5% delta‐9 tetrahydrocannabinol [THC]) after partial sleep deprivation (PSD)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Marijuana cigarette (0.003, 2, or 3.5% delta‐9 tetrahydrocannabinol [THC]) after regular sleep
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Marijuana cigarette (2% THC) after PSD
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Marijuana cigarette (3.5% THC) after PSD
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High‐potency marijuana
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Marijuana or PSD
Number of subjects: 7
Study: 10540058

Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 100 mg immediately post-induction
Number of subjects: 0
Study: 8871583

Group type: EXPERIMENTAL
Intervention: Reading aloud a piece of text (task a)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Reading silently (task b)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Speaking spontaneously (task c)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Making sounds without speaking (task d)
Number of subjects: 13
Study: 1751464

Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin
Number of subjects: 84

Group type: COMPARATOR
Intervention: 0.5% chloramphenicol
Number of subjects: 84
Study: 7006789

Group type: EXPERIMENTAL
Intervention: CCNU (100 mg/m2 p.o. q. 6 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: BCNU (200 mg/m2 p. 6 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CCNU
Number of subjects: 60

Group type: COMPARATOR
Intervention: BCNU
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-responders
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CCNU and BCNU
Number of subjects: 60
Study: 30767788

Group type: EXPERIMENTAL
Intervention: Citrulline (2 g/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 29717699

Group type: EXPERIMENTAL
Intervention: Self-Management education (SMILE (UK))
Number of subjects: 404

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 404
Study: 26214075

Group type: EXPERIMENTAL
Intervention: Olfactory prime (clean, citrus smell)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual prime (male eyes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual prime (female eyes)
Number of subjects: 0
Study: 24816219

Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP) with DN ≥ 50 milliseconds
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP) with DN < 50 milliseconds
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 286
Study: 23010339

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotic treatment for 48 hours
Number of subjects: 46

Group type: COMPARATOR
Intervention: Broad-spectrum antibiotic treatment for 7 days
Number of subjects: 46
Study: 20363908

Group type: EXPERIMENTAL
Intervention: Materialistic pursuits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experiential pursuits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Materialistic purchases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Materialistic people
Number of subjects: 0
Study: 18375021

Group type: EXPERIMENTAL
Intervention: PCV7 (7-valent pneumococcal conjugate vaccine) administered > or =7 days before DTaP
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: PCV7 (7-valent pneumococcal conjugate vaccine) administered with DTaP
Number of subjects: 800

Group type: COMPARATOR
Intervention: DTaP only
Number of subjects: 800
Study: 15671975

Group type: EXPERIMENTAL
Intervention: Intravenous glycopyrrolate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 38
Study: 12789978

Group type: EXPERIMENTAL
Intervention: Sonicare toothbrush
Number of subjects: 0
Study: 10321444

Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol 5/50 mg o.d. (Logimax)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Captopril-hydrochlorothiazide 25/25 mg o.d. (Capozide)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol 10/100 mg o.d. (Logimax)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Captopril-hydrochlorothiazide 50/25 mg o.d. (Capozide)
Number of subjects: 109
Study: 7900559

Group type: EXPERIMENTAL
Intervention: Doyle II silicone stents
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nasal packing (from 1989 study)
Number of subjects: 20
Study: 2672775

Group type: EXPERIMENTAL
Intervention: Orthotopic liver transplantation
Number of subjects: 0
Study: 907011

Group type: EXPERIMENTAL
Intervention: Instructional manuals alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Training groups
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Telephone consultations
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Training groups plus home visits
Number of subjects: 160

Group type: COMPARATOR
Intervention: Delayed-treatment control group
Number of subjects: 160
Study: 30740658

Group type: EXPERIMENTAL
Intervention: Interventions based on gait analysis (including physical therapy, orthotics, spasticity management, and orthopedic surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 28320541

Group type: EXPERIMENTAL
Intervention: Ketorolac (20 mg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Prednisolone (30 mg)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 25869627

Group type: EXPERIMENTAL
Intervention: Single dose of cycloserine (250, 500, or 1000 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple doses of cycloserine 250 mg BID for 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study: 23700804

Group type: EXPERIMENTAL
Intervention: Submandibular gland transfer
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 65
Study: 21091100

Group type: COMPARATOR
Intervention: Baseline BMI
Number of subjects: 83

Group type: COMPARATOR
Intervention: Skinfold thickness
Number of subjects: 83

Group type: COMPARATOR
Intervention: Changes in BMI
Number of subjects: 83

Group type: COMPARATOR
Intervention: Changes in waist circumference
Number of subjects: 83

Group type: COMPARATOR
Intervention: Baseline CRF
Number of subjects: 83
Study: 19625125

Group type: EXPERIMENTAL
Intervention: Duloxetine (60-120 mg/day)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 17277995

Group type: EXPERIMENTAL
Intervention: Patient Navigator (PN)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Usual Care (C)
Number of subjects: 125
Study: 15144908

Group type: EXPERIMENTAL
Intervention: Beclomethasone (800 microg/d for 12 weeks)
Number of subjects: 45
Study: 11977322

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 9701895

Group type: EXPERIMENTAL
Intervention: Haematinic supplementation for 8 weeks
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Haematinic supplementation
Number of subjects: 300
Study: 8273133

Group type: EXPERIMENTAL
Intervention: EPO 150 units/kg
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: EPO 300 units/kg
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: EPO 600 units/kg
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: EPO (all doses)
Number of subjects: 116
Study: 2528983

Group type: EXPERIMENTAL
Intervention: h alpha CGRP infusion (1.5 micrograms min‐1 i.v.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 10
Study: 818752

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside (Ara‐A)
Number of subjects: 0
Study: 30998610

Group type: EXPERIMENTAL
Intervention: Intracoronary thrombolysis (IT group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Thrombus aspiration (TA group)
Number of subjects: 71
Study: 28887378

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 3876

Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 3876
Study: 26256216

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic therapies (NPTs) provided to nursing home residents, including an online course for physicians and a 1-day seminar for nurses.
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Therapeutic NPT prescribed by physicians.
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Nursing education on pain-management techniques.
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: NPT received by residents.
Number of subjects: 239
Study: 24054342

Group type: EXPERIMENTAL
Intervention: Comprehensive daily symptom diary intervention with self-care education and counseling at baseline and 5 follow-up calls for 3 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 44
Study: 22287401

Group type: EXPERIMENTAL
Intervention: Repeated bolus injections (40 mg dose, twice per day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Continuous infusion (80 mg per day mixed with 5% glucose)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both administration methods (repeated bolus and continuous infusion)
Number of subjects: 32
Study: 19429721

Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound (EBUS)
Number of subjects: 58

Group type: COMPARATOR
Intervention: High‐resolution CT (HRCT) scanning
Number of subjects: 58
Study: 16394797

Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin treatment in IVDUs
Number of subjects: 406
Study: 12699093

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair under general anaesthesia (n = 237)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Mesh plug insertion under monitored local, epidural, or spinal anaesthesia (n = 234)
Number of subjects: 471
Study: 10499944

Group type: EXPERIMENTAL
Intervention: ST-segment elevation measurements by emergency physicians, residents, and students
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Threshold of at least 2.0 mm for ST-segment elevation
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intraobserver measurements of paired ST-segment elevations
Number of subjects: 52
Study: 8750275

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy and autologous bone marrow support (ABMS) without induction chemotherapy (Upfront cohort)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Induction chemotherapy with doxorubicin, 5-fluorouracil and methotrexate prior to high-dose chemotherapy and ABMS (AFM cohort)
Number of subjects: 64
Study: 1776388

Group type: EXPERIMENTAL
Intervention: Selegiline (30 mg/day for 8 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (for 4 weeks)
Number of subjects: 18
Study: 7008941

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6329980

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg X 2/die) and sucralfate (1 gr X 2/die)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ranitidine only
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cimetidine 1 g/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cimetidine 800 mg/b.i.d.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sucralfate 3 g/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pirenzepine 150 mg/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sulglycotide 0.5‐1 g/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 29460914

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27663365

Group type: EXPERIMENTAL
Intervention: Adipose-derived MSCs
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived MSCs
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fibroblasts
Number of subjects: 15
Study: 24785761

Group type: EXPERIMENTAL
Intervention: Striatal dopamine D2/3 receptor availability in obese subjects
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amphetamine-induced dopamine release in controls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amphetamine-induced dopamine release in obese subjects
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison of dopamine release between groups
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation of dopamine release with food craving in obese subjects
Number of subjects: 30
Study: 22468623

Group type: EXPERIMENTAL
Intervention: Heat-killed Lactobacillus plantarum L-137 (10 mg tablet)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (matching tablet)
Number of subjects: 16
Study: 20212198

Group type: EXPERIMENTAL
Intervention: Patching plus telescopic magnification
Number of subjects: 15

Group type: COMPARATOR
Intervention: Patching alone
Number of subjects: 15
Study: 18517083

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray, 110 microg once daily
Number of subjects: 183

Group type: COMPARATOR
Intervention: Prednisone, 10 mg once daily
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 15860944

Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jojoba oil massage
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 0
Study: 12406021

Group type: EXPERIMENTAL
Intervention: Sterol-enriched margarine providing 3.2 g of plant sterols daily for 3 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control margarine for 3 weeks
Number of subjects: 88
Study: 10591389

Group type: COMPARATOR
Intervention: High-intensity oral anticoagulants (INR, 2.8-4.8)
Number of subjects: 10056

Group type: COMPARATOR
Intervention: Moderate oral anticoagulants (INR, 2-3)
Number of subjects: 10056

Group type: COMPARATOR
Intervention: Moderate- to high-intensity oral anticoagulants (INR, >=2)
Number of subjects: 10056

Group type: COMPARATOR
Intervention: Moderate- to high-intensity oral anticoagulants and aspirin
Number of subjects: 10056

Group type: COMPARATOR
Intervention: Low-intensity oral anticoagulants (INR, <2.0) and aspirin
Number of subjects: 10056
Study: 7726444

Group type: EXPERIMENTAL
Intervention: Regular, sugar-free chewing gum
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Nicotine gum 2 mg
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control (overnight fast)
Number of subjects: 104
Study: 2139175

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 42
Study: 7018181

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31485039

Group type: EXPERIMENTAL
Intervention: EyeCee One IOL
Number of subjects: 80

Group type: COMPARATOR
Intervention: iMics1 IOL
Number of subjects: 80
Study: 30732139

Group type: EXPERIMENTAL
Intervention: Training with cup-type N95 respirator
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Training with fold-type N95 respirator
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Training with valve-type N95 respirator
Number of subjects: 23
Study: 27265181

Group type: EXPERIMENTAL
Intervention: Leucine-rich whey protein beverage (LWH)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Soy protein (SOY)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Soy protein + 3 g HMB (HMB)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isocaloric carbohydrate (CHO)
Number of subjects: 8
Study: 25412432

Group type: EXPERIMENTAL
Intervention: Immediate Post‐Concussion Assessment and Cognitive Testing (ImPACT)
Number of subjects: 0
Study: 24298492

Group type: EXPERIMENTAL
Intervention: Deep Cervical Flexor (DCF) training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional Isometric Training (CIT)
Number of subjects: 30
Study: 21793279

Group type: EXPERIMENTAL
Intervention: 1000 mg low molecular weight iron-dextran intravenously in two doses (Group A)
Number of subjects: 135

Group type: COMPARATOR
Intervention: 800 mg daily for 30 days of iron protein-succinylate (Group B)
Number of subjects: 135
Study: 19194455

Group type: EXPERIMENTAL
Intervention: Silicone earplugs
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no earplugs)
Number of subjects: 34
Study: 17324285

Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard of care (placebo cohort from literature)
Number of subjects: 37
Study: 15220185

Group type: EXPERIMENTAL
Intervention: Low intensity with IL-6 infusion (LO + IL-6)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low intensity without IL-6 infusion (LO)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High intensity (HI)
Number of subjects: 6
Study: 12457389

Group type: EXPERIMENTAL
Intervention: Preventive interventions evaluated in the PACE Clinic program.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biological and psychological processes investigated.
Number of subjects: 0
Study: 10413652

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma) therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 7560771

Group type: EXPERIMENTAL
Intervention: Biovisc (1% sodium hyaluronate)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Healonid
Number of subjects: 106
Study: 1792112

Group type: EXPERIMENTAL
Intervention: Edu‐K movement
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Repatterned Edu‐K movements
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (sat quietly for 10 minutes)
Number of subjects: 20
Study: 7171413

Group type: EXPERIMENTAL
Intervention: Systemically administered diamorphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caudal analgesia with 0.5% bupivacaine plain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caudal analgesia with 0.5% bupivacaine plain and morphine sulphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Injected diamorphine
Number of subjects: 0
Study: 29512121

Group type: EXPERIMENTAL
Intervention: Intra-articular ketorolac (5 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 44
Study: 26460629

Group type: EXPERIMENTAL
Intervention: L-DOPA (Sinemet®)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 24261316

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg once daily added to gabapentin (maximum 2400 mg daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Gabapentin monotherapy
Number of subjects: 8
Study: 21431338

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RXU)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: RelyX Unicem with selective enamel etching (RXU+E)
Number of subjects: 34
Study: 21309476

Group type: EXPERIMENTAL
Intervention: 5 mg plain bupivacaine plus 25 mg meperidine (BM25)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 10 mg hyperbaric bupivacaine (HB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 5 mg plain bupivacaine plus 35 mg meperidine (BM35)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 5 mg plain bupivacaine plus 30 mg meperidine (BM30)
Number of subjects: 80